MGX stock icon

Metagenomi
MGX

$3.73
3.61%
 

About: Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).

Employees: 236

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 9 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

13,298,462,300% more capital invested

Capital invested by funds: $0 [Q4 2023] → $133M (+$133M) [Q1 2024]

4,800% more funds holding

Funds holding: 0 [Q4 2023] → 48 (+48) [Q1 2024]

4,800% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 0

100% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 1 (+1) [Q1 2024]

33.7% more ownership

Funds ownership: 0% [Q4 2023] → 33.7% (+33.7%) [Q1 2024]

Research analyst outlook

9 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$6
61%
upside
Avg. target
$17.11
359%
upside
High target
$25
570%
upside

9 analyst ratings

positive
89%
neutral
11%
negative
0%
HC Wainwright & Co.
Mitchell Kapoor
168%upside
$10
Buy
Reiterated
15 May 2024
HC Wainwright & Co.
Mitchell Kapoor
168%upside
$10
Buy
Initiated
7 May 2024
JP Morgan
Brian Cheng
61%upside
$6
Neutral
Downgraded
2 May 2024
Chardan Capital
Geulah Livshits
463%upside
$21
Buy
Maintained
28 Mar 2024
Wells Fargo
Yanan Zhu
570%upside
$25
Overweight
Initiated
5 Mar 2024

Financial journalist opinion